Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.

Instead, evidence pointed to a weak ability of PDE5 inhibitors to counteract prostate cancer phenotypes, although in most cases these effects failed to reach statistical significance ( Figure 2 , Figure 3 ). siRNA-based PDE5A knockdown confirmed with statistical significance both the modest effect size and the tumor suppressive direction of these effects ( Figure 4 ).

also in 6,035 other papers